Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

The vote followed the board’s action in July to lower the estimated cost of phase one from $445 million to $425 million, creating a savings of $20 million. That was possible because of bids coming in ...

This paper presents a method to compute the saddle-node bifurcation points (SNB) of distribution networks and verifies the existence of saddle-node bifurcations in 3-phase distribution networks with ...

NOW Inc. (NYSE: DNOW), Houston, TX, announced this week that Sonya Reed has been appointed to the company’s board of directors effective this past Wednesday. Reed’s term will expire at the 2022 annual ...

In this paper, a metasurface for generating broadband deflection vortex beams based on the Pancharatnam-Berry (PB) phase principle is proposed. The units with different phase responses are arranged ...